x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

The Readout Loud

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

business

All Episodes

33:14

279: Live from the 2023 STAT Summit

The Readout Loud ·

2023/10/19

Live from Boston at the 2023 STAT Summit, we discuss the latest news in the life sciences, including a milestone in genome editing, a twist in the search for ALS treatments, and the polarizing process of saying words in biotech.

en

32:57

278: Merger Mondays, Ozempic panic, & CRISPR'd pigs

The Readout Loud ·

2023/10/12

We discuss Bristol Myers Squibb’s multibillion-dollar acquisition of Mirati Therapeutics and what it means for a biotech sector still in a slump. We also explain the latest news in the life sciences, including Wall Street’s freakout over GLP-1, CRISPR’ing animals, and the latest in the NASH saga.

en

31:06

277: Is the Nobel committee evolving? Plus,...

The Readout Loud ·

2023/10/05

It’s Nobel week on the podcast, and reporter Megan Molteni details the unique story of this year’s winners for medicine, Katalin Karikó and Drew Weissman. Then, our colleague Jason Mast joins us to explain the scientific and ethical quandaries facing the teams attempting to develop HIV vaccines.

en

34:47

276: Who discovered GLP-1? Plus: BrainStorm at the...

The Readout Loud ·

2023/09/28

Our colleague Elaine Chen joins us to explain the story of Svetlana Mojsov, a chemist who played a vital role in the discovery of GLP-1 who has spent decades fighting for proper recognition. We also discuss the latest news in the life sciences, including the FDA hearing on a BrainStorm Cell Therapeutics' polarizing ALS treatment, the end of the road for a once-vaunted drug developer, and the sorry state of biotech stocks.

en

33:03

275: A thorny ALS debate at the FDA, and the promise...

The Readout Loud ·

2023/09/21

Our colleague Lizzy Lawrence joins us to explain the promise of artificial wombs and the debate over how to ethically develop them. We also discuss a momentous upcoming meeting in which FDA will consider the thorny case of a potential medicine for ALS whose supporting evidence has polarized patients and physicians.

en

39:27

274: Covid’s latest surge, Alnylam at the FDA, & the...

The Readout Loud ·

2023/09/14

Our colleague Helen Branswell joins us to discuss the state of the Covid-19 pandemic heading into the fall and the rollout of boosters shots aimed at the latest viral variants. We also discuss the latest news in the life sciences, including an IPO implosion, a debate at the FDA, and the ups and downs of a career in biotech.

en

33:31

273: Back to school for biotech, Biogen's potential...

The Readout Loud ·

2023/09/07

Josh Schimmer and Eric Schmidt, two longtime analysts teaming up at Cantor Fitzgerald, join us for a back-to-school conversation as biotech enters the busy back third of 2023. We also discuss the latest news in the life sciences, including some scientific evolution at Biogen, new leadership at Illumina, and the future of CRISPR medicine.

en

29:30

272: Vivek's star turn, leaky drug data, & biotech as...

The Readout Loud ·

2023/08/24

We discuss how Vivek Ramaswamy, fresh off his headline-grabbing debut at the first Republican presidential debate, went from a drug industry entrepreneur to a GOP rising star — and how his former biotech colleagues are reacting to it. We also explain the latest news in the life sciences, including a curious data leak and the family business of a famed biotech inventor.

en

34:56

271: Racing for gene therapy, a pioneering approval,...

The Readout Loud ·

2023/08/18

Our colleague Jason Mast joins us to explain how the approval of a landmark gene therapy for Duchenne muscular dystrophy set in motion a frantic race to get children treated before their 6th birthdays. Then, HSBC Managing Director Jonathan Norris calls in to discuss why so many biotech startups are facing financial bridges to nowhere.

en

32:52

270: Your guide to Wegovy’s blockbuster heart study

The Readout Loud ·

2023/08/10

In the wake of a massively important clinical trial of Novo Nordisk’s obesity drug Wegovy, our colleague Elaine Chen joins us to explain what we know and don’t know about data that could change the practice of medicine. Then, Mizuho Securities biotech strategist Jared Holz calls in to discuss whether explosive popularity of obesity treatments could help create the first trillion-dollar drug company.

en

37:27

269: Biotech layoffs, eye drug drama, & gene therapy...

The Readout Loud ·

2023/08/03

First, we discuss how some recent layoffs and a reverse merger mean for biotech in 2023. We’ll also discuss the latest news in the life sciences, including a dramatic saga in ocular medicine, the volatile business of Covid-19, and some major milestones in gene therapy.

en

36:25

268: Biogen's sticky situation, Wegovy's risks, &...

The Readout Loud ·

2023/07/27

First, we discuss why Wall Street was less than convinced by Biogen's attempt to assuage concerns about its credibility. Then we explain an insider trading scandal that bridges biotech and elite-level soccer, the latest concerns over Wegovy, and the rest of the week's news in the life sciences. We also break some bittersweet news, with the help of some headline names from around biotech.

en

35:26

267: BridgeBio's big week, Lilly's Alzheimer's data,...

The Readout Loud ·

2023/07/20

Neil Kumar, CEO of BridgeBio, joins us to talk about how his small company came to develop what could be a big drug — and why classical Greek literature remains relevant. We also discuss the latest news in the life sciences, including the abrupt resignation of the celebrity scientist who led Stanford University and the implications of tornado damage at a Pfizer plant.

en

32:42

266: Wegovy in the brain, pivotal Alzheimer's data, &...

The Readout Loud ·

2023/07/13

Our colleague Megan Molteni joins us to explain the evolving science suggesting products like Wegovy are less weight loss drugs than treatments for human desire. We also explain why this summer is shaping up to be a pivotal moment for the treatment of Alzheimer’s and discuss our befuddlement with the latest social media platform.

en

35:01

265: Novavax's CEO promises a turnaround & how Lilly...

The Readout Loud ·

2023/06/29

Our colleague Elaine Chen joins us to explain how the era of Wegovy could be short-lived in light of powerful new weight-loss medicines from Eli Lilly. Then, John Jacobs, the new CEO of Novavax, stops by to explain his plan to right the ship at a company that has struggled to make the most of its potent Covid-19 vaccine.

en

36:35

264: Messy PBM conflicts, debatable vaccines, & the...

The Readout Loud ·

2023/06/22

Our colleague Bob Herman joins us to explain his year-long investigation into some brazen conflicts of interest in the world of prescription drug pricing. Then, STAT's Helen Branswell calls in to walk us through a news-packed week for vaccines, including weighty decisions for Covid-19 and RSV.

en

39:57

263: Biogen's messy board, Laronde's data problem, &...

The Readout Loud ·

2023/06/15

Our colleague Allison DeAngelis joins us to share her reporting on how the handsomely funded Laronde Therapeutics, billed as “Moderna 2.0,” ran into behind-the-scenes problems with its scientific data. We also discuss how Biogen's boardroom scandal has roiled a company that was supposed to be entering a new era.

en

29:52

262: Merck v. USA, the best of ASCO, and Leqembi at...

The Readout Loud ·

2023/06/08

STAT Washington correspondent Rachel Cohrs joins us to explain Merck's lawsuit against the federal government and why the company believes drug pricing negotiation is “tantamount to extortion." We also discuss the health effects of Canadian wildfires, the highlights of the year’s biggest cancer research conference, and what could be a watershed moment in the treatment of Alzheimer’s.

en

31:28

261: Fake medical devices, real cancer drugs, &...

The Readout Loud ·

2023/06/01

Our colleague Lizzy Lawrence joins us to explain the shocking story of a medical device company that sold fake implants and the warped system that made the scam lucrative. We’ll also preview the year’s biggest cancer research meeting and discuss a surprising twist with novel weight loss medicines.

en

31:18

260: ChatGPT in medicine, a boom in weight loss...

The Readout Loud ·

2023/05/25

As hospitals and health care companies are racing to implement large language models like ChatGPT into their businesses, STAT reporter Casey Ross joins us to explain what experts want the world to know before embracing generative AI. We also discuss the latest twist for Sarepta Therapeutics and the quest to develop more potent weight loss medicines.

en

381 results

Similar Podcasts

TaxTalent.com The Golden Rule Podcast

Adam Golden

TaxTalent.com Podcast

Tony Santiago

Handelsblatt Crime - spannende Streitfälle der deutschen Wirtschaft

Ina Karabasz, Solveig Gode, Sönke Iwersen

Deffner und Zschäpitz – Der Wirtschafts-Talk von WELT

WELT

Black Box - La scatola nera della finanza

Guido Brera e Gian Luca Comandini -...